(This Dec. 17 story has been corrected to say that the EU regulator reversed its July decision in November to recommend ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

Eli Lilly (LLY) stock in focus as China approves its Alzheimer's treatment Kisunla (donanemab). Read more here.

Shares of Biogen Inc. BIIB inched 0.31% higher to $150.49 Monday, on what proved to be an all-around mixed trading session ...

ADNOC Drilling , a unit of the United Arab Emirates' state oil giant, said on Tuesday it has closed an agreement to create ...

Shares of Biogen Inc. BIIB inched 0.10% higher to $150.64 Tuesday, on what proved to be an all-around grim trading session ...

The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen ...

CMS has reportedly directed Medicare Advantage plan providers to cover Biogen's drug Qalsody for ALS following reports it was ...

In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that ...

Biogen (BIIB) closed near a 52-week low of $150.03. The stock trades at a discount because the biotech firm lacks growth ...

Stifel downgraded Biogen Inc (NASDAQ:BIIB) stock to “hold” from “buy” as it noted the company was grappling with a challenging year due to a slow rollout of its Alzheimer’s drug, lecanemab.

It is hard to get excited after looking at Biogen's (NASDAQ:BIIB) recent performance, when its stock has declined ...